Overview

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Primary: • To evaluate the safety and tolerability of ADXS-504 and to determine the MTD or RP2D.
Phase:
Phase 1
Details
Lead Sponsor:
Mark Stein